Implanet plans to acquire a majority stake in Orthopaedic & Spine Development (OSD), developer and manufacturer of implants for spine surgery.
OSD’s lineup includes a range of cages, plates and fixation systems for lumbar and cervical applications.
Implanet’s offer is valued at €4.2 million (~USD $5.0 million) for 100% of the shares.
Ludovic Lastennet, CEO of Implanet, said “The acquisition of OSD represents a milestone in our strategy, deployed since late 2019, to strengthen Implanet’s position in the orthopedic and spine market. The clinical value of our JAZZ® technology has, over the years, enabled us to become a pivotal player in pediatric spinal deformity, but thus far our range has limited our ability to grow at a similar pace in the degenerative adult segment.
In 2020, Implanet announced its intent to divest knee replacement assets to focus on its spine portfolio.
“This merger with OSD will strengthen our spinal implant range, notably for the adult market, while positioning Implanet as an integrated supplier capable of competing with the market’s largest players. The merger will enable us to rapidly achieve a critical mass in terms of revenue. Reaching this critical mass will ensure that, in the coming years, we will be able to meet regulatory, clinical and economic demands in a fast-growing market.”
Implanet plans to acquire a majority stake in Orthopaedic & Spine Development (OSD), developer and manufacturer of implants for spine surgery.
OSD's lineup includes a range of cages, plates and fixation systems for lumbar and cervical applications.
Implanet's offer is valued at €4.2 million (~USD $5.0 million) for 100% of the...
Implanet plans to acquire a majority stake in Orthopaedic & Spine Development (OSD), developer and manufacturer of implants for spine surgery.
OSD’s lineup includes a range of cages, plates and fixation systems for lumbar and cervical applications.
Implanet’s offer is valued at €4.2 million (~USD $5.0 million) for 100% of the shares.
Ludovic Lastennet, CEO of Implanet, said “The acquisition of OSD represents a milestone in our strategy, deployed since late 2019, to strengthen Implanet’s position in the orthopedic and spine market. The clinical value of our JAZZ® technology has, over the years, enabled us to become a pivotal player in pediatric spinal deformity, but thus far our range has limited our ability to grow at a similar pace in the degenerative adult segment.
In 2020, Implanet announced its intent to divest knee replacement assets to focus on its spine portfolio.
“This merger with OSD will strengthen our spinal implant range, notably for the adult market, while positioning Implanet as an integrated supplier capable of competing with the market’s largest players. The merger will enable us to rapidly achieve a critical mass in terms of revenue. Reaching this critical mass will ensure that, in the coming years, we will be able to meet regulatory, clinical and economic demands in a fast-growing market.”
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.